



## SURGI-MAB AND QUEST MEDICAL IMAGING ENTER A COLLABORATION AGREEMENT FOR THE 1ST PHASE III MULTICENTER CLINICAL TRIAL ON FLUORESCENCE GUIDED SURGERY FOR DIGESTIVE CANCERS.

Montpellier, France and Middenmeer, Holland - 18 sept 2017 – SurgiMab, a biotechnology company which is developing cancer-specific fluorescent molecules for use in fluorescence-guided oncologic surgery and colorectal cancer screening, and Quest Medical Imaging, a leader in the market for multispectral cameras, announced today that they have entered into a collaboration agreement for the upcoming Phase III clinical trial of SurgiMab's SGM-101 in fluorescent guided colorectal cancer surgery.

Under the terms of the agreement, Quest Medical Imaging has received an undisclosed lump sum payment to provide 12 Spectrum™ platforms to the centers that will participate in the Phase III pivotal trial sponsored by SurgiMab. The Quest Spectrum™ Fluorescence Imaging Platform is designed and developed for open and minimally invasive fluorescence image-guided surgery with the capability for multiple wavelengths in a single system. It demonstrated high sensitivity and ease of use in a previous phase I/II clinical trial in conjunction with SGM-101. The preliminary results of this trial have been presented by the clinical teams at the World Molecular Imaging Congress that took place in Philadelphia in September ( <http://www.wmis.org/2017-world-molecular-imaging-congress/> ).

Françoise Cailler, CEO of SurgiMab, said "We are looking forward to working with Quest for the pivotal trial of our lead compound SGM-101. Indeed, SGM-101's cancer targeting properties give it the potential to facilitate the detection and visualization of malignant tissue when used during image guided surgery. Our hope is that this real-time visualization of tumor tissue by surgeons will lead to higher rates of total resection and therefore significant benefits to patients. The use of a CE-marked / FDA approved device shall simplify the regulatory requirements and we are confident that the quality of the data that we will generate will help us accelerate the development of SGM-101 and ensure a quick access to the market.."

Richard Meester, CEO of Quest Medical Imaging said "*We are excited to move forward with SurgiMab to Phase III in order to prove the utility of Image Guided Surgery, specifically in colorectal surgery which is the third most common type of cancer worldwide, affecting people all over the world. Working with SurgiMab and our technology to get to market with the products which improve patient care is a perfect example of what we work for.*"

## **About SurgiMab**

SurgiMab is a private biotech company created in July 2011. Its Lead product, SGM-101, is a cancer-specific molecule for use in near-infrared (NIR) fluorescence-guided oncologic surgery (FGOS). As opposed to an indiscriminate contrast agent, SGM-101's ability to specifically highlight malignant tissue during surgery enables real-time visualization of tumor margins, tumor spread and micro-tumors that are invisible to the naked eye. This enhanced visibility has potentially transformative benefits for patients through an increase in radical resection rates during surgery and improved cancer detection during colorectal screening.

## **About Quest Medical Imaging**

Quest Medical Imaging B.V. is a Dutch corporation, started in 2010 to develop Image Guided Surgery medical devices. The Spectrum Platform was CE and FDA approved in late 2015 for market entry on perfusion indications. Quest Medical Imaging B.V. is the market leader in providing devices with the ability to visualize multiple near infrared and visible imaging agents simultaneously which opens up new applications in the surgical field and beyond that have not been practiced yet. Quest Medical Imaging B.V. has a fast development pipeline of applications and technology to add to its current Quest Spectrum™ platform.

## **Contacts**

**SurgiMab** - Françoise Cailler, President & CSO - tel: +33 467 798381 - fcailler@surgimab.com

**Quest Medical Imaging** - Richard Meester, President & CEO - tel: +31 227 604046 - richard.meester@quest-mi.com